Is this Turn Therapeutics (TTRX) Form 4 a share purchase or sale in the market?

No, this Form 4 reflects a stock option grant as compensation, not a market trade. Gengos did not buy or sell shares on the open market; he received the right to purchase shares later, subject to vesting and plan conditions.

Turn Therapeutics (TTRX) grants director 95,000 stock options at $5.75

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Turn Therapeutics director Andrew Gengos received a grant of stock options covering 95,000 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments starting on June 30, 2026, contingent on his continued employment under the company’s 2025 Omnibus Incentive Plan. This is a compensation-related award, not an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gengos Andrew

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	95,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 95,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 95,000 options Exercise price: $5.75 per share Underlying shares: 95,000 shares +2 more

5 metrics

Options granted 95,000 options Stock option grant to director on June 4, 2026

Exercise price $5.75 per share Strike price for the 95,000 stock options

Underlying shares 95,000 shares Common stock underlying the granted options

Expiration date June 4, 2036 Option term end date

Vesting schedule 12 equal monthly installments Vesting begins June 30, 2026, subject to continued employment

Key Terms

Stock option (right to buy), exercise price, vesting, Omnibus Incentive Plan, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 5.7500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option will vest in twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Omnibus Incentive Plan financial

"Issuer's 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/08/2026 - 05:31 PM Accepted by SEC EDGAR 06/08/2026 - 05:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gengos Andrew

(Last)

(First)

(Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91362

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$5.75	06/04/2026		A		95,000		⁽¹⁾	06/04/2036	Common Stock	95,000	$0	95,000	D

Explanation of Responses:

1. The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Andrew Gengos	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Turn Therapeutics (TTRX) director Andrew Gengos report on this Form 4?

Andrew Gengos reported receiving a grant of stock options for 95,000 shares of Turn Therapeutics common stock. These options are a compensation award, not an open-market trade, and give him the right to buy shares later at a fixed exercise price.

How many Turn Therapeutics (TTRX) options were granted and at what exercise price?

The grant covers 95,000 stock options with an exercise price of $5.75 per share. This means Gengos can choose to buy up to 95,000 shares at $5.75 each in the future, regardless of the market price at that time.

When do Andrew Gengos’s Turn Therapeutics (TTRX) options vest?

The options vest in twelve equal monthly installments starting on June 30, 2026. Each month, a portion becomes exercisable, as long as Gengos remains employed and continues to meet the conditions of the 2025 Omnibus Incentive Plan governing the award.

When do the Turn Therapeutics (TTRX) stock options granted to Andrew Gengos expire?

The options expire on June 4, 2036, giving a long-term window to exercise. After that date, any unexercised options become worthless and can no longer be used to buy Turn Therapeutics common shares at the fixed exercise price.